Water-soluble triazapyridinophane-based complexing agents and corresponding fluorescent lanthanide complexes

US10597409B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10597409-B2
Application numberUS-201616060291-A
CountryUS
Kind codeB2
Filing dateDec 9, 2016
Priority dateDec 9, 2015
Publication dateMar 24, 2020
Grant dateMar 24, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention can be used for marking biological molecules.

First claim

Opening claim text (preview).

The invention claimed is: 1. A complexing agent of formula (I): wherein: the R 1 groups are identical and are either: —CO 2 H, or —PO(OH)R, wherein R is selected from the group consisting of: phenyl optionally substituted by an —SO 3 H group benzyl, methyl, ethyl, propyl, n-butyl, sec-butyl, isobutyl, and tent-butyl; the A 1 , A 2 groups are identical or different and are selected from the group consisting of: a group of formula -L 1 -E; a group of formula (II) and a group of formula (II′); the A 3 group is selected from the group consisting of: a group of formula —O-L 3 -G, a group of formula (II), a group of formula (II′), a group of formula (III), and a group of formula (III′); L 1 , L 2 and L 3 are identical or different and each represent a divalent linkage group; E is a group that renders the complexing agent water-soluble, chosen selected from the group consisting of: —SO 3 H, —PO(OH) 2 , —CO 2 H, —N + Alk 1 Alk 2 Alk 3 , a carbohydrate residue, a sulfobetaine; and a PEG group; G is a reactive group selected from the group consisting of: an acrylamide, an amine, an ester, an aldehyde, an alkyl halide, an anhydride, an aniline, an azide, an aziridine, a carboxylic acid, a diazoalkane, a haloacetamide, a halotriazine, dichlorotriazine, a hydrazine, an imido ester, an isocyanate, an isothiocyanate, a maleimide, a sulfonyl halide, a thiol, a ketone, an acid halide, a succinimidyl ester, a hydroxysuccinimidyl ester, a hydroxysulfosuccinimidyl ester, an azidonitrophenyl, an azidophenyl, a glyoxal, a triazine, and an acetylenic group; Alk 1 , Alk 2 , Alk 3 , which may be identical or different, each represent a (C 1 -C 6 )alkyl. 2. The complexing agent as claimed in claim 1 , wherein A 1 and A 2 are identical and are a group of formula (II) and A 3 is a group of formula (III). 3. The complexing agent as claimed in claim 1 , wherein A 1 is a group of formula (II), A 2 is an -L 1 -E group and A 3 is a group of formula (III). 4. The complexing agent as claimed in claim 1 , wherein A 1 and A 2 are identical and are groups of formula (II), and A 3 is a group of formula —O-L 3 -G. 5. The complexing agent as claimed in claim 1 , wherein A 1 and A 2 are identical and are groups of formula -L 1 -E and A 3 is a group of formula (III). 6. The complexing agent as claimed in claim 1 , wherein A 1 and A 2 are identical and are groups of formula (II′) and A 3 is a group of formula (III′). 7. The complexing agent as claimed in claim 1 , wherein A 1 is a group of formula (II′), A 2 is an -L 1 -E group and A 3 is a group of formula (III′). 8. The complexing agent as claimed in claim 1 , wherein A 1 and A 2 are identical and are groups of formula (II′), and A 3 is a group of formula —O-L 3 -G. 9. The complexing agent as claimed in claim 1 , wherein A 1 and A 2 are identical and are groups of formula -L 1 -E and A 3 is a group of formula (III′). 10. The complexing agent as claimed in claim 1 , wherein L 1 , L 2 and L 3 are selected from the group consisting of: a linear or branched C 1 -C 20 alkylene group optionally containing one or more double or triple bonds; a C 5 -C 8 cycloalkylene group, a C 6 -C 14 arylene group, said alkylene, cycloalkylene or arylene groups optionally containing one or more hetero atoms, or one or more carbamoyl or carboxamido groups, and said alkylene, cycloalkylene or arylene groups being optionally substituted by C 1 -C 8 alkyl, C 6 -C 14 aryl, sulfonate or oxo groups; and a group having one of the following formulae: wherein n, m, p, q are integers from 1 to 5. 11. The complexing agent as claimed in claim 1 , wherein the -L 3 -G group consists of (i) a reactive group G selected from the group consisting of: a carboxylic acid, an amine, a succinimidyl ester, a haloacetamide, a hydrazine, an isothiocyanate, and a maleimide group, and (ii) a spacer arm L 3 consisting of an alkylene group comprising from 1 to 5 carbon atoms. 12. The complexing agent as claimed in claim 1 , wherein L 1 is a divalent group of formula: where n is an integer from 1 to 5. 13. The complexing agent as claimed in claim 1 , wherein L 2 is a divalent group of formula: where n and m are integers from 1 to 5. 14. The complexing agent as claimed in claim 1 , wherein L 3 is a divalent group of formula: —(CH 2 ) n — where n is an integer from 1 to 5. 15. A fluorescent lanthanide complex comprising a complexing agent as claimed in claim 1 and a lanthanide selected from the group consisting of: Eu 3+ , Sm 3+ , and Tb 3+ . 16. A fluorescent lanthanide complex of formula (IV), (V), (VI) or (VII) below: wherein: Ln 3+ is chosen from: Eu 3+ , Tb 3+ , Sm 3+ ; R 3 is chosen from the following groups: OH; 17. A fluorescent conjugate of a molecule of interest selected from the group consisting of: an amino acid, a peptide, a protein, an antibody, a sugar, a carbohydrate chain, a nucleoside, a nucleotide, an oligonucleotide, and an enzyme substrate, said molecule being covalently conjugated with a lanthanide complex as claimed in claim 15 . 18. The complexing agent as claimed in claim 1 , wherein the reactive group G is a group having one of the following formulae: wherein w varies from 0 to 8 and v is equal to 0 or 1, and Ar is a saturated or unsaturated 5- or 6-membered heterocycle, comprising 1 to 3 heteroatoms, optionally substituted by a halogen atom. 19. The fluorescent conjugate of claim 17 , wherein the molecule is the enzyme substrate and is selected from the group consisting of: a benzylguanine, a benzylcytosine, a chloroalkane and a coenzyme A.

Assignees

Inventors

Classifications

  • containing three or more hetero rings · CPC title

  • C07F5/003Primary

    without C-Metal linkages · CPC title

  • Rare earth chelates · CPC title

  • with fluorescent label · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10597409B2 cover?
The invention can be used for marking biological molecules.
Who is the assignee on this patent?
Cisbio Bioassays, Univ Toulouse, Centre Nat Rech Scient
What technology area does this patent fall under?
Primary CPC classification C07F5/003. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).